Pharmacokinetics of Doxycycline Hydrochloride Administered by Intravenous Infusion in Healthy Chinese Volunteers

被引:0
作者
Wu, Jing-li [1 ,4 ]
Zhang, Zun-jian [1 ,4 ]
Tian, Yuan [1 ,4 ]
Chen, Yun [2 ,3 ]
机构
[1] China Pharmaceut Univ, Ctr Instrumental Anal, Nanjing 210009, Peoples R China
[2] Peking Union Med Coll, Nanjing, Peoples R China
[3] Chinese Acad Med Sci, Inst Dermatol, Nanjing, Peoples R China
[4] China Pharmaceut Univ, Key Lab Drug Qual Control & Pharmacovigilance, Minist Educ, Nanjing 210009, Peoples R China
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2009年 / 59卷 / 01期
关键词
Antibiotics; CAS; 24390-14-5; Doxycycline hydrochloride; intravenous infusion; multiple-dose; pharmacokinetics; single-dose; Tetracyclines; BIOAVAILABILITY;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The pharmacokinetics of doxycycline hydrochloride (CAS 24390-14-5) was investigated In 11 healthy Chinese volunteers after single- and multiple-dose Intravenous (i. v.) Infusion. This study was conducted according to an open, randomized, four-period design with a one-week washout period separating each trial period. Single-dose studies with 100, 200, and 300 mg doxycycline were performed in the first three periods by a replicated 3 x 3 Latin square crossover design. Multiple-dose studies with once-daily 100 mg doxycycline for 7 consecutive days were performed in the last treatment period. Blood samples for pharmacokinetic profiling were taken up to 48 It post-infusion. Doxycycline hydrochloride plasma concentrations were determined with a validated liquid chromatography-ultraviolet (HPLC-UV) method. The pharmacokinetic parameters for single- and multiple-dose administration were estimated as follows: Maximum plasma concentrations (C-max) amounted to 1.49 +/- 0.59 mu g/mL (single, 100 mg doxycycline), 4.20 +/- 1.34 mu g/mL (single, 200 mg doxycycline), 6.69 +/- 1.26 mu g/mL (single-dose, 300 mg doxycycline) and 3.05 +/- 0.92 mu g/mL (multiple-dose, 100 mg doxycycline). The median T-max (2 h of infusion Included) was 2.00 +/- 0.19 h, 1.93 +/- 0.23 h, and 1.98 +/- 0.18 h for single dose of 100 mg, 200 mg, 300 mg doxycycline and 2.11 +/- 0.17 h for multiple dose of 100 mg doxycycline, respectively. Plasma elimination half-lives (t(1/2)) were 14.00 +/- 5.88 h, 14.20 +/- 8.11 h, 16.66 +/- 7.12 h and 14.03 +/- 3.50 h, areas under the plasma concentration-time curve (AUC(0-infinity)) were 21.85 +/- 6.37 mu g.h/mL, 52.02 +/- 15.26 mu g.h/mL, 84.86 +/- 23.03 mu g.h/mL and 34.64 +/- 5.89 mu g.h/mL, AUC(0-48) were 19.75 +/- 6.60 mu g.h/mL, 46.13 +/- 12.21 mu g.h/mL, 75.57 +/- 20.31 mu g.h/mL and 32.03 +/- 5.70 mu g.h/mL, for single dose of 100, 200, 300 mg doxycyctine and multiple dose of 100 mg doxycycline, respectively. AUC In the single-dose study were dose proportional, doxycycline hydrochloride showed first order kinetics in the range of 100-300 mg. The plasma concentration of doxycycline hydrochloride has been sustained at a certain effective level after multiple-dose treatment, and the elimination process was similar to that after the single dose. Gender differences were also observed.
引用
收藏
页码:49 / 54
页数:6
相关论文
共 50 条
  • [21] Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers
    Flanagan, Shawn
    Minassian, Sonia L.
    Prokocimer, Philippe
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (06):
  • [22] Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers
    Xiao, Y.
    Lu, Y.
    Kang, Z.
    Hou, F.
    Wang, S.
    Li, T.
    Liu, Y.
    Xia, Y.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (04) : 172 - 179
  • [23] Pharmacokinetics and Safety of Two Voriconazole Formulations after Intravenous Infusion in Healthy Korean Volunteers
    Cho, Sang-Heon
    Kim, Cheol-Woo
    Nam, Moon-Suk
    INFECTION AND CHEMOTHERAPY, 2020, 52 (02) : 204 - 211
  • [24] Pharmacokinetics of leflunomide in Chinese healthy volunteers
    Li, J
    Yao, HW
    Jin, Y
    Zhang, YF
    Li, CY
    Li, YH
    Xu, SY
    ACTA PHARMACOLOGICA SINICA, 2002, 23 (06) : 551 - 555
  • [25] Pharmacokinetics of rosuvastatin in Chinese healthy volunteers
    Yu-qing, Zhanghong Xiong
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 219 - 219
  • [26] Pharmacokinetics of Febuxostat in Healthy Chinese Volunteers
    Liu, X. -X.
    Liu, R. -J.
    Ding, L.
    Lin, Y. -F.
    Huang, N. -Y.
    Xiao, H. -F.
    Huang, Y.
    Yang, J.
    Wang, S. -L.
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 (10): : 463 - 469
  • [27] Pharmacokinetics of oral and intravenous melatonin in healthy volunteers
    Lars P. H. Andersen
    Mads U. Werner
    Mette M. Rosenkilde
    Nathja G. Harpsøe
    Hanne Fuglsang
    Jacob Rosenberg
    Ismail Gögenur
    BMC Pharmacology and Toxicology, 17
  • [28] Pharmacokinetics of oral and intravenous melatonin in healthy volunteers
    Andersen, Lars P. H.
    Werner, Mads U.
    Rosenkilde, Mette M.
    Harpsoe, Nathja G.
    Fuglsang, Hanne
    Rosenberg, Jacob
    Gogenur, Ismail
    BMC PHARMACOLOGY & TOXICOLOGY, 2016, 17
  • [29] Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion
    Burgess, DS
    Summers, KK
    Hardin, TC
    CLINICAL THERAPEUTICS, 1999, 21 (11) : 1882 - 1889
  • [30] The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers
    Moore, KHP
    Leese, PT
    McNeal, S
    Gray, P
    O'Quinn, S
    Bye, C
    Sale, M
    CLINICAL THERAPEUTICS, 2002, 24 (04) : 583 - 594